Difference between revisions of "Nadofaragene firadenovec (Adstiladrin)"
Jump to navigation
Jump to search
m |
m (→Also known as) |
||
| Line 9: | Line 9: | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' SCH 721015 | + | *'''Code name:''' SCH-721015 |
*'''Generic name:''' nadofaragene firadenovec-vncg | *'''Generic name:''' nadofaragene firadenovec-vncg | ||
*'''Brand name:''' Adstiladrin, Instiladrin | *'''Brand name:''' Adstiladrin, Instiladrin | ||
Revision as of 12:55, 8 September 2023
General information
From the NCI Drug Dictionary: A replication-deficient recombinant adenovirus encoding human interferon alpha-2b with potential antineoplastic activity. Upon intravesical administration, nadofaragene firadenovec infects nearby tumor cells and expresses INF alpha-2b intracellularly which activates the transcription and translation of genes whose products mediate antiviral, antiproliferative, antitumor, and immune-modulating effects.
Diseases for which it is used
History of changes in FDA indication
- 2022-12-16: Initial approval for adult patients with high-risk Bacillus Calmette-Guérin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. (Based on rAd-IFN-CS-003)
Also known as
- Code name: SCH-721015
- Generic name: nadofaragene firadenovec-vncg
- Brand name: Adstiladrin, Instiladrin